Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs High-dose Clopidogrel in HPR Patients Post-PCI
NCT03078465Phase 3Withdrawn
- Sponsor
- Nanjing First Hospital
- Start
- Jun 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ticagrelor in coronary artery disease (CAD), sponsored by Nanjing First Hospital. Planned start Jun 2017; status: withdrawn.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03078465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078465.